These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 16979439)

  • 1. Radioimmunotherapy in a radiation oncology environment: building a multi-specialty team.
    Macklis RM
    Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S4-6. PubMed ID: 16979439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioimmunotherapy for non-Hodgkin's lymphoma: a review for radiation oncologists.
    Macklis RM; Pohlman B
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):833-41. PubMed ID: 16965871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioimmunotherapy as a therapeutic option for Non-Hodgkin's lymphoma.
    Macklis RM
    Semin Radiat Oncol; 2007 Jul; 17(3):176-83. PubMed ID: 17591564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Future directions in radioimmunotherapy for B-cell lymphoma.
    Horning SJ
    Semin Oncol; 2003 Dec; 30(6 Suppl 17):29-34. PubMed ID: 14710401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
    Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
    J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Logistics of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
    Zimmer AM
    Semin Nucl Med; 2004 Jan; 34(1 Suppl 1):14-9. PubMed ID: 14762740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma.
    Gordon LI; Witzig TE; Wiseman GA; Flinn IW; Spies SS; Silverman DH; Emmanouilides C; Cripe L; Saleh M; Czuczman MS; Olejnik T; White CA; Grillo-López AJ
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):87-92. PubMed ID: 11842394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical considerations and radiation safety in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
    Gordon LI
    Semin Oncol; 2003 Dec; 30(6 Suppl 17):23-8. PubMed ID: 14710400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Logistics of therapy with the ibritumomab tiuxetan regimen.
    Meredith RF
    Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S35-8. PubMed ID: 16979437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody.
    Wagner HN; Wiseman GA; Marcus CS; Nabi HA; Nagle CE; Fink-Bennett DM; Lamonica DM; Conti PS
    J Nucl Med; 2002 Feb; 43(2):267-72. PubMed ID: 11850494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma.
    Marcus R
    Semin Oncol; 2005 Feb; 32(1 Suppl 1):S36-43. PubMed ID: 15786024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioimmunotherapy for non-Hodgkin's lymphoma with yttrium 90 ibritumomab tiuxetan.
    Hendrix CS; de Leon C; Dillman RO
    Clin J Oncol Nurs; 2002; 6(3):144-8. PubMed ID: 11998607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin): the role of the nuclear medicine physician.
    Conti PS
    Semin Nucl Med; 2004 Jan; 34(1 Suppl 1):2-3. PubMed ID: 14762737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ongoing investigations and new uses of radioimmunotherapy in the treatment of non-Hodgkin's lymphoma.
    Meredith RF
    Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S23-9. PubMed ID: 16979435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 90Y-ibritumomab tiuxetan: rationale for patient selection in the treatment of indolent non-Hodgkin's lymphoma.
    Grillo-López AJ
    Semin Oncol; 2005 Feb; 32(1 Suppl 1):S44-9. PubMed ID: 15786025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioimmunotherapy for B-cell non-Hodgkin lymphoma.
    Witzig TE
    Best Pract Res Clin Haematol; 2006; 19(4):655-68. PubMed ID: 16997175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiation safety considerations with yttrium 90 ibritumomab tiuxetan (Zevalin).
    Zhu X
    Semin Nucl Med; 2004 Jan; 34(1 Suppl 1):20-3. PubMed ID: 14762741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioimmunotherapy of Non-Hodgkin B-cell Lymphoma: An update.
    Cicone F; Santo G; Bodet-Milin C; Cascini GL; Kraeber-Bodéré F; Stokke C; Kolstad A
    Semin Nucl Med; 2023 May; 53(3):413-425. PubMed ID: 36635112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
    Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
    J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New strategies in radioimmunotherapy for lymphoma.
    Pandit-Taskar N; Hamlin PA; Reyes S; Larson SM; Divgi CR
    Curr Oncol Rep; 2003 Sep; 5(5):364-71. PubMed ID: 12895386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.